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ABSTRACT
The capability to derive endothelial cell (ECs) from induced pluripotent stem cells (iPSCs) holds
huge therapeutic potential for cardiovascular disease. This study elucidates the precise role of
the RNA-binding protein Quaking isoform 5 (QKI-5) during EC differentiation from both mouse
and human iPSCs (hiPSCs) and dissects how RNA-binding proteins can improve differentiation
efﬁciency toward cell therapy for important vascular diseases. iPSCs represent an attractive cel-
lular approach for regenerative medicine today as they can be used to generate patient-speciﬁc
therapeutic cells toward autologous cell therapy. In this study, using the model of iPSCs differ-
entiation toward ECs, the QKI-5 was found to be an important regulator of STAT3 stabilization
and vascular endothelial growth factor receptor 2 (VEGFR2) activation during the EC differentia-
tion process. QKI-5 was induced during EC differentiation, resulting in stabilization of STAT3
expression and modulation of VEGFR2 transcriptional activation as well as VEGF secretion
through direct binding to the 30 UTR of STAT3. Importantly, mouse iPS-ECs overexpressing QKI-5
signiﬁcantly improved angiogenesis and neovascularization and blood ﬂow recovery in experi-
mental hind limb ischemia. Notably, hiPSCs overexpressing QKI-5, induced angiogenesis on
Matrigel plug assays in vivo only 7 days after subcutaneous injection in SCID mice. These results
highlight a clear functional beneﬁt of QKI-5 in neovascularization, blood ﬂow recovery, and
angiogenesis. Thus, they provide support to the growing consensus that elucidation of the
molecular mechanisms underlying EC differentiation will ultimately advance stem cell regenera-
tive therapy and eventually make the treatment of cardiovascular disease a reality. The RNA
binding protein QKI-5 is induced during EC differentiation from iPSCs. RNA binding protein QKI-
5 was induced during EC differentiation in parallel with the EC marker CD144. Immunoﬂuores-
cence staining showing that QKI-5 is localized in the nucleus and stained in parallel with CD144
in differentiated ECs (scale bar5 50 mm). STEM CELLS 2017; 00:000–000
INTRODUCTION
Cardiovascular disease is a leading cause of
mortality worldwide with pathology being sig-
niﬁcantly driven by progressive vascular endo-
thelial cell (EC) dysfunction which regulates
key pathogenic events such as inﬁltration of
inﬂammatory cells, vascular smooth muscle
proliferation, and platelet aggregation [1, 2].
As cardiovascular disease progresses, ECs
become depleted from the vascular lumen,
and, without adequate replacement, non-
perfusion and tissue ischaemia ensues. Repair
and regeneration of ECs has been an impor-
tant research focus for many years. As an
important therapeutic avenue, the delivery of
adult progenitor or stem cells to repair dam-
aged vasculature has faced many limitations,
such as identiﬁcation and availability of appro-
priate, efﬁcacious cell-types for therapy [3].
However, recently, the ability to derive ECs
from induced pluripotent stem cells (iPSCs)
has extended the scientiﬁc scope for regenera-
tive medicine [4, 5, 7].
Cell reprogramming is offering new ave-
nues for regenerative medicine with iPSCs
proving able to differentiate into nearly all
types of cells within the body [6–8]. This is a
unique characteristic of iPSC technology, which
offers a signiﬁcant potential for cell-based
therapies toward repairing tissues or organs
destroyed by injury, degenerative diseases,
aging, or cancer [4, 5, 8, 9]. Generation of
iPSCs also offers a promising strategy to create
patient-speciﬁc cells [7, 10–13] with building
evidence that these cells have therapeutic
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REGENERATIVE MEDICINE
efﬁcacy in animal models of disease [3, 5, 14–16]. The con-
cept of cell reprogramming is powerful [17–20] and has, so
far, allowed the development of dynamic approaches to gen-
erate functional cells of interest and to switch cell fate [20].
We and others have recently demonstrated novel strategies
of direct reprogramming toward functional ECs [21, 22]. Both
iPSCs and directly reprogrammed cells (partial iPSC–PiPSCs)
can serve as useful tools not only for derivation of functional
cells but also for establishing efﬁcient protocols of differentia-
tion and developing platforms to investigate the underlying
mechanisms.
Vascular cell differentiation is achieved through the coor-
dination of diverse molecular pathways [21, 23–28]. Due to
this, there is a need to better understand the complex
dynamics behind RNA regulation and how this, in turn, inﬂu-
ences transcriptional control and protein expression. Elucida-
tion of these complex molecular signals, which are evoked
during iPSC and PiPSC differentiation toward ECs, may allow
speciﬁc targeting of their activities to enhance cell differentia-
tion and promote tissue regeneration. In an effort to eluci-
date the imperative mechanisms of RNA regulation during EC
differentiation from iPSCs, this study focused on the RNA-
binding protein Quaking (QKI). QKI is a member of the “STAR”
(signal transduction and activation of RNA) family of proteins.
These proteins are characterized by the presence of at least
one RNA-binding motif (QKI containing a KH domain), SH2
and SH3 domains and potential phosphorylation sites. This
suggests their involvement in signal transduction pathways
[29, 30], pre-mRNA splicing [31], exportation of mRNAs from
the nucleus [32], protein translation, and mRNA stability.
Functional studies of the mouse QKI gene have revealed that
it has a key function in embryonic blood vessel formation and
remodeling [33–35, 37]. During vascular cell differentiation
and reprogramming processes, QKI could play an important
regulatory role in gene expression at the post-transcriptional
level in either a miRNA-dependent or independent manner.
Alternative splicing of genes, a process that RNA binding pro-
teins are highly involved in, generates many forms of mature
mRNA from the same gene is an essential process in develop-
ment and a potent way to regulate gene expression at a post-
transcriptional level. QKI has a number of alternative splicing
isoforms, three of which have been associated with vascular
development; QKI-5, QKI-6, and QKI-7. This further reinforces
the importance of QKI in protein regulation and development.
Each isoform contains identical RNA binding domains and dif-
fers only by its carboxy-terminal ends [36, 37]. In this study,
we focus on the QKI splicing isoform 5 (QKI-5). QKI-5 is most
highly expressed during EC differentiation from iPSCs, it is an
essential player during embryogenesis and notably, QKI-5 null
mice are embryonic lethal [38, 39, 41].
We provide strong evidence that QKI-5 plays a critical role
in the differentiation of ECs derived from iPSCs and acts as a
key regulator of CD144 stabilization and vascular endothelial
growth factor receptor 2 (VEGFR2) activation through STAT3
signaling. The RNA binding protein QKI-5 directly binds to 30
UTR of STAT3 and induced STAT3 mRNA stabilization. Remark-
ably, QKI-5 improved neovascularization and blood ﬂow recov-
ery in a hind limb ischemic model. Notably, human iPSCs
(hiPSCs) overexpressing QKI-5 (OE-QKI-5) induced angiogenesis
in Matrigel plug assays in vivo only 7 days after subcutaneous
injection in SCID mice, highlighting, thus, a pivotal role of
QKI-5 in neovascularization, blood ﬂow recovery and
angiogenesis.
MATERIALS AND METHODS
Cell culture media, serum, and cell culture supplements were
purchased from ATCC, England, UK, https://www.lgcstandards-
atcc.org/?geo_country=gb Millipore, LONZA; England, UK,
http://www.lonza.com/ and Thermo Fisher Scientiﬁc; England,
UK, http://www.thermoﬁsher.com/uk/en/home.html. Anti-
bodies against VE-cadherin (CD144) (ab33168), PECAM (CD31)
(ab28364), Flk-1 (ab9530), STAT3 (ab119352), pSTAT3
(ab76315), JAK-1 (ab47435), GAPDH (ab8245), OCT4 (ab19857),
eNOS (ab66127), and QKI (ab126742) were purchased from
Abcam. Antibodies against vWF (SC-8068) and QKI (SC-103851)
were purchased from Santa Cruz; Heidelberg, Germany,
https://www.scbt.com/scbt/home;jsessionid=jQ9cedHXnegG6a6c
JZbpXPfwu6Z4K8PRhaZidcYh8LrI_ccsHWgp!-97074204#. Anti-
bodies against QKI-5 (AB 9904) were purchased from Millipore;
England, UK, http://www.merckmillipore.com/GB/en?Referrer
URL=http%3A%2F%2Fwww.bing.com%2Fsearch%3Fq%3Dmillipore%
26src%3DIE-TopResult%26FORM%3DIETR02%26conversationid%3D.
Mouse iPSC and Embryonic Stem Cell Culture and
Differentiation
Mouse iPSCs were generated in our laboratory using a similar
approach as described previously [20, 40]. Mouse iPSCs were
cultured in gelatin-coated ﬂasks (phosphate buffer saline
[PBS] containing 0.02% gelatin from bovine skin; Sigma-
Aldrich, SIGMA; England, UK http://www.sigmaaldrich.com/
united-kingdom.html) in Dulbecco’s modiﬁed Eagle’s medium
(ATCC) supplemented with 10% fetal bovine serum (FBS), 100
IU/ml penicillin, and 100 lg/ml streptomycin (Thermo Fisher
Scientiﬁc), 10 ng/ml recombinant human leukemia inhibitory fac-
tor (Millipore); and 0.1 mM 2-mercaptoethanol (Invitrogen) in a
humidiﬁed incubator supplemented with 5% CO2. The cells were
passaged every 2 days at a ratio of 1:6. Differentiation of iPSCs
was induced by seeding the cells on type IV mouse collagen (5
lg/ml)-coated dishes in differentiation media (DM) containing
a-modiﬁed Eagle’s medium supplemented with 10% FBS (Invitro-
gen), 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin, and
100 lg/ml streptomycin in the presence of 25 ng/ml VEGF for
the time points indicated.
hiPSCs Differentiation and Human Umbilical Vein ECs
hiPSCs were pre-differentiated in low attachment plates using
StemPro serum free media supplemented with Bone Morpho-
genetic Protein 4 (BMP4), Activin A, ﬁbroblast growth factor
(FGF), and VEGF for 5 days. The pre-differentiated cells were
seeded on ﬁbronectin (Sigma-Aldrich), while KDR endothelial
precursor cells were magnetically sorted on day 6 using
MicroBeads Kit (Miltenyi BIotec) and culturing in EGM-2
media (LONZA) for 3–9 days. QKI-5 was overexpressed or
knockdown by lentiviral gene transfer on day 3 after KDR
selection and the cells were harvested on day 3 and subjected
to further analysis or labeled for the in vivo Matrigel plug
assays. Human umbilical vein ECs (HUVECs) were seeded on
collagen I coated plates and cultured in EGM-2 media. QKI-5
was overexpressed by lentiviral gene transfer and subjected
to further analysis.
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Experimental Hind Limb Ischemia
The mouse hind limb ischemia model was performed as
described previously [21, 42]. iPS-ECs were infected with
FUW-QKI-5 or control empty vectors on day 4 of EC differenti-
ation. After 48 hours, the cells were trypsinized and labeled
with Molecular Probes Vybrant Cell Labeling (MP22885)
before being injected intramuscularly into the adductors of
C57BL/6 wild type mice.
Statistical Analysis
Data are expressed as the mean6 SEM and were analyzed
using GraphPad Prism 5 software with a two-tailed Student’s t
test for two groups or pairwise comparisons or analysis of
variance (ANOVA). A value of *, p< .05; *, p< .05; **,
p< .01; ***, p< .001 was considered signiﬁcant.
Detailed Methods and Materials are in Supporting Infor-
mation Appendix, Experimental Procedures
RESULTS
Pluripotent Stem Cells Differentiation toward ECs
Mouse iPSCs were differentiated toward ECs by seeding on
collagen IV and DM supplemented with 25 ng/ml VEGF
(DM1V) for 2–10 days. The differentiated ECs adopted a typ-
ical EC morphology (Fig. 1A, 1B). The efﬁciency of EC differen-
tiation from mouse iPSCs was very high as FACs analysis is
shown in Figure 1C (86.7% positive cells for CD144 [VE-Cad-
herin] and 87.2% positive cells for CD31 were obtained).
These results were conﬁrmed in both mRNA (Fig. 1D) and
protein levels (Fig. 1E, 1F). During EC differentiation the plu-
ripotent marker OCT4 was suppressed allowing the expression
of the EC speciﬁc markers CD144 and CD31 to occur in a time
point dependent manner (Fig. 1F). Indeed, immunoﬂuores-
cence confocal microscope images revealed that ECs derived
from iPSCs expressed EC markers (CD144, FLK-1, eNOS, and
vWF) which are the characteristics of ECs (Fig. 1G). We also
observed that the expression of the transcription factor STAT3
is a known essential player in VEGF signaling during vascular
development. We are reporting that STAT3 was progressively
induced during EC differentiation (Fig. 1H). Taken together,
these data clearly demonstrate that mouse iPSCs have been
differentiated toward ECs based on a highly efﬁcient
approach.
RNA-Binding Protein QKI Is Induced during EC
Differentiation from iPSCs
QKI-5 was signiﬁcantly induced during EC differentiation from
iPSCs and this occurred in parallel with the EC markers CD144
and CD31 (Fig. 2A). It is important to note that only QKI-5
mRNA splicing isoform was induced during EC differentiation.
QKI-6 and QKI-7 expression levels were also tested showing
no change or decrease, respectively (Fig. 2A). Time-course
experiments also demonstrated that QKI-5 was progressively
induced after 4 days post-differentiation from iPSCs (Fig. 2B).
There was a comparable induction of CD144 and STAT3 (Fig.
2B). Immunoﬂuorescence images demonstrated that the alter-
native splicing isoform QKI-5 was localized to the EC nucleus
in both mouse iPSC-derived ECs and in HUVECs (Fig. 2C–2E).
Also in both EC-types, CD144 and CD31 were expressed in the
plasma membrane (Fig. 2D, 2E). These results demonstrated
that QKI-5 expression is induced during EC differentiation
from mouse iPSCs, and its expression is maintained in mature
ECs.
A number of additional experiments were performed to
determine whether QKI-5 plays a regulatory role in iPSC dif-
ferentiation toward ECs. Initially, a pure population (100%) of
differentiated ECs was obtained based on CD144 selection, as
it is a robust EC-speciﬁc marker. Based on this pure popula-
tion of ECs derived from iPSCs, a high expression of QKI-5
was observed and this was comparable to the EC markers
CD144, VEGFA, and the transcription factor STAT3 (Supporting
Information Fig. S1A–S1F).
Further experiments performed on mouse embryonic
stem cells (ESCs) differentiated to ECs, using a similar
approach as the iPSCs, veriﬁed that QKI-5 expression was
induced in parallel with CD144 expression (Supporting Infor-
mation Fig. S2A–S2D). These results indicated that QKI-5 may
be implicated in differentiation of ECs derived from mouse
iPSC and ESCs. To elucidate the underlying mechanisms regu-
lated by QKI-5 in EC differentiation, QKI-5 was overexpressed
by lentiviral gene transfer at day 4 of EC differentiation using
ECs derived from iPSCs. The cells were harvested on day 6
and subjected to further analysis. QKI-5 overexpression signiﬁ-
cantly enhanced expression of the endothelial markers CD144,
CD31, eNOS, and VEGFA and the transcription factor STAT3
(Fig. 2F, 2G). Surprisingly, QKI-5 overexpression also induced
the in activation of the CD144 (VE-Cadherin) promoter as
revealed by luciferase assays (Fig. 2H).
Importantly, QKI-5 also induced the expression of the arte-
rial speciﬁc EC marker Ephrin B2, but it did not affect the
expression of venous (CoupTFII) and lymphatic (Lyve1)
markers. Moreover, QKI-5 induced EC differentiation in an EC-
speciﬁc manner, while markers of other cells lineages such as
neuronal (Nestin), cardiac (Mef2c), or smooth muscle cell
(SMA) were not altered by QKI-5 overexpression (Fig. 2I).
These data reveal that QKI-5 induced EC differentiation
toward an arterial lineage.
QKI-5 Is Capable of Initiating EC Differentiation from
iPSCs
Further experiments have revealed that QKI-5 leads to the
stabilization of VE-Cadherin adhesion molecule during the EC
differentiation process. When differentiated ECs were treated
with Actinomycin D for 6 hours or cyclohexamide for 24
hours, CD144 (VE-Cadherin) expression was stabilized in the
presence of QKI-5 (Supporting Information Fig. S3A–S3D),
respectively. Moreover, when differentiated ECs were treated
with Actinomycin D in a time point experiment from 0 to 24
hours, CD144 expression was stabilized as a decay curve as is
shown in Supporting Information Figure S3E. These results
demonstrate that QKI-5 induced the expression and stabiliza-
tion of CD144 during EC differentiation. Additional experi-
ments have been conducted to address the important
question whether QKI-5 is able to initiate EC differentiation
from iPSCs. When QKI-5 was overexpressed in undifferentiat-
ed iPSCs, the cells started expressing the arterial marker Eph-
rin B2 3 days later, while venous, lymphatic, or markers of
other cell lineages, such as Nestin and SMA, were not
expressed (Supporting Information Fig. S4A). Importantly, EC
markers were highly induced upon QKI-5 overexpression in
Cochrane, Kelaini, Tsifaki et al. 3
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Figure 1. Induced pluripotent stem cell differentiation toward endothelial cells (ECs). Mouse induced pluripotent stem cells (iPSCs)
were cultured on 0.02% gelatin with media supplemented with leukaemia inhibitory factor (LIF) to maintain pluripotency. To induce EC
differentiation iPSCs were seeded onto plates coated with collagen IV and differentiation media supplemented with 25 ng/ml vascular
endothelial growth factor (DM1V). (A): Schematic representation showing differentiation process. (B): Images show morphology of
iPSCs (left panel) and of their differentiated EC counterparts (right panel) scale bar5 50 lm. (C): FACs analysis showing expression of
CD144 (left panel) and CD31 (right panel) of ECs derived from iPSCs. (D, F): EC marker expression increased in a time-dependent man-
ner during differentiation at both mRNA and protein level, while the pluripotent marker OCT4 decreased during EC differentiation in a
time-dependent manner (data are mean6 SEM (n5 3), *, p< .05; ***, p< .001). (E): Immunoﬂuorescence confocal image showing that
the 6 days differentiated ECs express the EC speciﬁc marker CD144, scale bar5 50 lm. (G): iPS-ECs expressed EC markers CD144, FLK-1,
eNOS, and VWF as shown by confocal immunoﬂuorescent images, scale bar5 50 lm. (H): The transcription factor STAT3 was progres-
sively expressed during EC differentiation (data are mean6 SEM [n5 3], *, p< .05). Abbreviations: DAPI, 40,6-Diamidine-20-phenylindole
dihydrochloride; DM, differentiation medium; EC, endothelial cell; iPSC, induced pluripotent stem cell; VEGF, vascular endothelial growth
factor.
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Figure 2. The RNA binding protein QKI-5 is induced during endothelial cell (EC) differentiation from induced pluripotent stem cells (iPSCs).
(A): RNA binding protein QKI-5 was induced during EC differentiation in parallel with the EC markers CD144 and CD31.The expression levels of
QKI-6 and QKI-7 were not changed or decreased, respectively. (B): Western blots showing that QKI-5 protein was progressively expressed in
parallel with the EC marker CD144 and the transcription factor STAT3 in time point experiments from 0 to 10 days during EC differentiation.
(C): Immunoﬂuorescence staining showing that QKI-5 is localized in the nucleus and in parallel with CD144 in differentiated ECs (D) (scale
bar5 50 mm) and (E) with CD31 in mature ECs (human umbilical vein ECs), scale bar5 25 mm. (F): iPS-ECs were infected or transfected on day
4 with QKI-5 or an empty vector. After 48 hours, QKI-5 overexpression induced mRNA expression of endothelial markers CD144, CD31, eNOS,
VEGFA, and the transcription factor STAT3. (G): QKI-5 induced protein expression of CD144. (H): iPS-ECs were differentiated for 3 days and
transfections with the reporter of CD144 (VE-cadherin) construct (pGL3-Luc-CD144) in the presence or absence of QKI-5 were performed. Cells
were harvested on day 5 of EC differentiation when luciferase assays demonstrated that QKI-5 induced transcriptional activation of the VE-
cadherin promoter. (I): iPS-ECs were differentiated for 4 days and transfected with QKI-5 or an empty vector. After 48 hours, QKI-5 overexpres-
sion directed differentiation toward arterial ECs (Ephrin B2) speciﬁcally and not toward venous (CoupTFII) or lymphatic (Lyve1) ECs or other tis-
sues such as nerve (Nestin), cardiac (Mef2c) or smooth muscle cell (SMA) (data are means6 SEM [n5 3]; *, p< .05; **, p< .01; ***,
p< .001). Abbreviations: CTL, control; EC, endothelial cell; iPSC, induced pluripotent stem cell.
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early stages of EC differentiation (Supporting Information Fig.
S4B). Finally, to shed light on the upstream signaling, which
activates QKI-5 expression in early stages of EC differentiation
from iPSCs, transcription factor binding analysis on the QKI-5
promoter has predicted a potential binding site for the tran-
scription factor ETS1. ETS factors, and in particular ETS1 and
Etv2, have been reported as key factors that regulate endo-
thelial development [43]. Interestingly, ETS1 is induced during
EC differentiation from iPSCs in a time-dependent manner
(Supporting Information Fig. S4C), while overexpression of
ETS1 in early stages of EC differentiation has led to induction
of QKI-5 (Supporting Information Fig. S4D). These results dem-
onstrate that QKI-5 is able to initiate EC differentiation from
iPSCs, and ETS1 may be implicated in the activation of QKI-5
in the early stages of EC differentiation.
QKI-5 Induced VEGFR2 Activation and VEGF Secretion
through Direct Binding of the 30UTR Region of STAT3
Formation of vascular networks is highly dependent on VEGF
as a critical regulator of EC differentiation and vasculogenesis
during development. Overexpression of QKI-5 by lentiviral
gene transfer induced the secretion of VEGF on day 6 during
the EC differentiation process (Fig. 3A). Similarly, QKI-5 over-
expression led to activation of VEGFR2 during EC differentia-
tion from iPSCs (Fig. 3B). To shed light on the signaling
cascade initiated by the VEGFR transcriptional activation, the
expression of the transcription factors STAT3, JAK-1, and AP-1
was assessed. Over-expression of QKI-5 leads to enhanced
transcriptional activation of the VEGFR2 signaling pathway,
which seems to be related to increased expression of VEGFA
and autocrine stimulation of its cognate receptor (Fig. 3C).
Notably, overexpression of QKI-5 induced the expression of EC
markers, CD144 and CD31, in parallel with the induction of
JAK-1, STAT3, and phosphorylation of STAT3 (Fig. 3D, and
quantiﬁcation in Fig. 3E). These results revealed that QKI-5 is
implicated in the activation of the VEGFR2-regulatory binding
sites AP1, STAT3, as well as STAT3 phosphorylation. Additional
experiments were performed to investigate the nature of QKI-
5-mediated activation of VEGFR. When STAT3 was knocked
down by shRNA during EC differentiation, the previously
observed upregulation of EC markers (CD144, CD31, and
eNOS) and VEGFA, mediated by QKI-5 was ablated (Fig. 3F).
Furthermore, luciferase assays revealed that knockdown of
STAT3 by shRNA ablated the QKI-5-mediated activation of
VEGFR2 (Supporting Information Fig. S5A). In agreement with
the above results, when the differentiated ECs were treated
with inhibitors to block the JAK-1 and STAT3 pathways, QKI-5
did not activate the EC markers CD31, CD144, eNOS, FLK-1
(VEGFR2), and VEGFA (Supporting Information Fig. S5B). Taken
together, these data demonstrate that QKI-5 modulates the
activation of VEGFR and EC differentiation through the tran-
scription factor STAT3. Interestingly, the KH DOMAIN-mutant
QKI-5 constructs did not induce the expression of the EC
markers and STAT3 signaling when it was overexpressed in
the iPSCs (Supporting Information Fig. S6A–S6D). These results
suggest that QKI-5 binds candidate RNAs in the JAK1-STAT3
signaling pathway and regulates EC differentiation. Important-
ly, luciferase assays have shown that QKI-5 activated the
30UTR of STAT3. Remarkably, QKI-5 was unable to activate the
30UTR of STAT3 when the QKI motif was deleted (Fig. 3G).
Moreover, RNA binding assays have conﬁrmed that QKI binds
directly to the 30UTR of STAT3 (Fig. 3G, lower panel). More-
over, when differentiated ECs were treated with Actinomycin
D in a time point experiment from 0 to 24 hours, STAT3
expression was stabilized as a decay curve is shown in Figure
3H. These results clearly demonstrate that the RNA binding
protein QKI-5 induced VEGFR2 activation and VEGF secretion
through direct binding of the 30UTR of STAT3.
QKI-5 Has a Critical Role during EC Differentiation and
Vascular Tube Formation
When QKI-5 expression was suppressed by shRNA during EC
differentiation, this resulted in a signiﬁcant suppression of the
EC markers CD144 and CD31 (Fig. 4A, 4B) and the transcrip-
tion factor STAT3 (Fig. 4B). Moreover, knockdown of QKI-5
caused inhibition in the transcriptional activation of VEGFR
(Fig. 4C). Furthermore, knockdown of QKI-5 by shRNA resulted
in inhibition of angiogenesis in Matrigel plugs in vivo (Fig.
4D), which further reinforced the notion that QKI-5 plays a
critical role during EC differentiation and subsequent angio-
genic function of the derived cells.
QKI-5 Induced Angiogenesis in Both in Vitro and in
Vivo
QKI-5 appears to play an important role in iPSC-derived ECs
during the formation of vascular networks in vitro and in vivo.
These processes are greatly dependent on the presence of
VEGF, although these experiments were conducted in the
absence of exogenous VEGF. Notably, overexpression of QKI-5
by lentiviral gene transfer induced vascular tube formation in
vitro (Fig. 4E, quantiﬁed in the right panel as total tube
length/ﬁeld [mM]) and vessel formation in vivo (Fig. 4F, quan-
tiﬁed in the right panel as capillary density) when compared
with controls. CD144 immunoﬂuorescence staining veriﬁed
the presence of differentiated cells in in vivo vascular tubes
and demonstrated that QKI-5 over-expressing iPSCs displayed
well-formed vascular structures and enhanced engraftment
ability when compared with the control cells (Fig. 4G). More-
over, the nascent vessels in vivo (matrigel plugs) were stabi-
lized by pericytes/vascular smooth muscle cells in the
presence of QKI-5 as smooth muscle alpha-actin (SMA) stain-
ing is shown in Supporting Information Figure S7. These
results demonstrate that QKI-5 induced the angiogenesis in
both in vitro and in vivo Matrigel plug assays.
QKI-5 Significantly Improved Neovascularization and
Blood Flow Recovery in the Hind Limb Ischemic Model
ECs derived from mouse iPSCs (iPS-ECs CTL) or iPSC ECs OE-
QKI-5 (iPS-ECs OE-QKI-5) were labeled with Vybrant and
injected intramuscularly immediately after induction of hind
limb ischemia in mice. PBS was also used as an additional
control. After 7 and 14 days, delivery of iPS- ECs OE-QKI-5
improved neovascularization and promoted signiﬁcantly higher
blood ﬂow in the ischemic limbs compared to the non-
modiﬁed, iPS-ECs controls or PBS controls (Fig. 5A–5D). Limbs
receiving iPS-ECs OE-QKI-5 also displayed signiﬁcantly higher
capillary numbers in the musculature in comparison with the
controls (Fig. 5E, 5F) as shown by staining of adductor muscle
sections with CD144 (Fig. 5G) and CD31 (Supporting Informa-
tion Fig. S8A) in immunopositive vessel proﬁles. Notably,
engrafted iPS-ECs OE-QKI-5 displayed a typical vascular
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Figure 3. QKI-5 induced vascular endothelial growth factor receptor 2 (VEGFR2) activation and VEGF secretion through direct binding
of the 30UTR region of STAT3. Overexpression of QKI-5 by lentiviral gene transfer induced the secretion of VEGF on day 6 of the endo-
thelial cell (EC) differentiation process (A) and the transcriptional activation of the VEGFR2 (B). (C): Real time polymerase chain reaction
(PCR) data showing that QKI-5 leads to activation of VEGFA, JAK-1, STAT3, and AP1. (D): Western blots showing that overexpression of
QKI-5 induced the expression of EC markers CD144, and CD31 in parallel to induction of JAK-1, STAT3, and phosphorylation of STAT3
(quantiﬁcation in E). (F): STAT3 was knocked down by shRNA on day 3 of EC differentiation, and QKI-5 was overexpressed next day. Real
data PCR data reveal that STAT3 knocked down ablated activation of EC markers CD31, CD144, eNOS, and VEGFA mediated by QKI-5.
The cells were harvested on day 6 of EC differentiation. (G): Luciferase assays have shown that QKI-5 activated the 30UTR of STAT3. QKI-
5 was unable to activate the 30UTR of STAT3 when the QKI motif was deleted. (G, lower panel) RNA binding assays have conﬁrmed that
QKI binds directly to the 30UTR of STAT3. (H): When differentiated ECs were treated with Actinomycin D in a time point experiment
from 0 to 24 hours STAT3 expression was stabilized as a decay curve is shown (data are means6 SEM [n5 3]; *, p< .05). Abbreviations:
CTL, control; VEGF, vascular endothelial growth factor.
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Figure 4. QKI-5 plays a critical role during endothelial cell (EC) differentiation and vascular tube formation both in vitro and in vivo.
QKI-5 knockdown by shRNA in iPS-ECs at day 4 of differentiation resulted in suppression of (A) mRNA expression of the EC markers
CD144 and CD31 (data are means6 SEM [n5 3]; *, p< .05), and (B) protein expression of CD144 and the transcription factor STAT3,
when assessed on day 6. (C): shRNA knockdown of QKI-5 resulted in suppression of the transcriptional activity of the vascular endotheli-
al growth factor receptor 2 (VEGFR2) during EC differentiation, as shown by luciferase assays. Nontargeting (NT) control for knockdown
experiments using shRNA. These experiments were performed on day 3 and analysed on day 5 of EC differentiation (data are means6
SEM [n5 3]; *, p< .05). (D): shRNA knockdown of QKI-5 during EC differentiation suppressed the formation of vascular-like tubes in
vivo in Matrigel plug assays. iPS-ECs were infected with QKI-5 shRNA on day 4 of EC differentiation, and 48 hours later, mixed with
Matrigel and subcutaneous injected in to mice, prior to analysis of Matrigel plugs 7 days later; scale bar5 50 mm. Induced pluripotent
stem cells were seeded on collagen IV-coated plates and cultured in differentiated media in the absence of VEGF for 4 days when QKI-5
or control plasmids were introduced by lentiviral gene transfer. Two days later, cells were mixed with Matrigel for in vitro plug assays.
(E): QKI-5 formed vascular structures within a few hours in vitro in comparison with the control where less deﬁned vascular structures
were observed (e, left panel, with right panel showing quantiﬁcation as total tube length/ﬁeld (mm) (data are means6 SEM [n5 3]; *,
p< .05). (F): Similarly, cells were subjected to Matrigel plug assays in vivo which showed that QKI-5-expressing cells form well-deﬁned
vascular structures at 7 days in comparison with the control where less well-formed vascular structures were observed ((F) left panel,
with quantiﬁcation of capillary density [number per square millimeter] in the right panel) (data are means6 SEM [n5 3]; *, p< .05).
(G): Frozen sections from the in vivo Matrigel plugs were stained for CD144 to demonstrate that overexpression of QKI-5 induced the
formation of vascular structures and enhanced engraftment ability compared with the control cells (data are means6 SEM [n5 3]; *,
p< .05). Scale bar5 50 mm. Abbreviations: CTL, control; EC, endothelial cell.
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Figure 5. QKI-5 signiﬁcantly improved neovascularization and blood ﬂow recovery in experimental hind limb ischemia. Endothelial cells
(ECs) derived from induced pluripotent stem cells (iPS-ECs), iPS-ECs OE-QKI-5 (iPS-QKI-5-ECs) labeled with Vybrant, or phosphate buffer
saline (PBS) as a control were injected intramuscularly immediately after induction of hind limb ischemia. (A–C): Laser Doppler images
of blood ﬂow (BF) in the lower limbs of mice in prone position, with the ischemic leg highlighted by the white rectangle. (D): Time
course of BF recovery in the ischemic foot (calculated as a percentage ratio between ischemic foot BF and the contralateral foot BF) for
each of the three conditions. Statistical analysis shows signiﬁcantly higher BF recovery in the iPS-EC QKI-5 treated mice at 7 and 14
days in comparison with PBS control and also comparing iPS-ECs to iPS-ECs- OE-QKI-5; Bonferroni post test (to one way analysis of vari-
ance) conﬁrms signiﬁcant difference after 14 days between iPS-ECs and iPS-ECs overexpressing QKI-5; *, p< .05; **, p< .01; ***,
p< .001 (data are means6 SEM [n5 3]) (E, F): Sections of adductor muscles were stained with CD144 or CD31 antibody and (G) capil-
lary density expressed as capillary number per mm2, and (E, F) further co-stained with CD144 (green) and Vybrant (red) prior to (H)
quantiﬁcation (and for CD31 please see Supporting Information Fig. S4A, S4B) *, p< .05; ***, p< .001 data are mean6 SEM, quantiﬁca-
tion from four random microscopic ﬁelds at 340, scale bar5 50 lm). Abbreviations: CTL, control; EC, endothelial cell; iPSC, induced plu-
ripotent stem cell; OE, overexpressing; PBS, phosphate buffered saline.
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architecture, while in the PBS control experiments, a random
pattern and no vascular structures were observed (Fig. 5E,
5F).
Finally, when adductor muscle sections from iPS-ECs CTL
or iPS- ECs OE-QKI-5 injected animals were stained and quan-
tiﬁed with Vybrant and EC markers, iPS- ECs OE-QKI-5 were
found to display an enhanced engraftment ability compared
with controls (Fig. 5H; Supporting Information Fig. S8B). These
results indicate that iPS-ECs OE-QKI-5 display characteristic
endothelial functions when tested in vivo. Importantly, no
tumors have been detected in any animals during the dura-
tion of these experiments highlighting that these pluripotent
stem cells were fully differentiated into ECs.
QKI-5 Has a Key Role in EC Differentiation Derived
from hiPSCs
Generation of high-ﬁdelity and stable EC populations, derived
from human pluripotent cells, is a major limitation that the
EC differentiation and cell reprogramming ﬁeld are facing at
the moment. Thus, we investigated whether QKI-5 has a role
in EC differentiation derived from hiPSCs. hiPSCs were gener-
ated and differentiated in low attachment plates using Stem-
Pro serum free media supplemented with BMP4, Activin A,
FGF, and VEGF for 5 days. Then, a KDR positive population
was selected and cultured in Fibronectin coated plates supple-
mented with EGM-2 media for 3–9 days. The derived hiPSC-
ECs displayed a typical pattern of EC speciﬁc markers such as
CD144, CD31, eNOS, and vWF (Fig. 6A). The efﬁciency of EC
differentiation from hiPSCs was 62% as shown by FACs analy-
sis for the positive cells for the EC marker CD144 (Fig. 6B).
QKI-5 was expressed during EC differentiation from hiPSCs in
parallel with VE-cadherin expression (Fig. 6C, 6D). QKI-5 over-
expression by lentiviral gene transfer signiﬁcantly induced the
expression of the EC markers CD144, CD31, and eNOS (Fig. 6E,
6F and signaling of VEGFR [KDR], VEGFA, and STAT3 during EC dif-
ferentiation (Fig. 6G). Further data from luciferase assays also
conﬁrmed that QKI-5 induced the transcriptional activation of
CD144 and VEGFR in human cells (Fig. 6H, 6I). In contrast, knock-
down of QKI-5 by shRNA suppressed the transcriptional activa-
tion of both CD144 and VEGFR (Fig. 6H, 6I). Importantly, QKI-5
only induced the expression of arterial speciﬁc EC marker and
not the expression of venous and lymphatic markers (Fig. 6J).
These data reveal that QKI-5 is implicated in EC differentiation
from hiPSCs toward an arterial EC speciﬁcation.
hiPSC-ECs OE-QKI-5 Induced Angiogenesis in Vivo
As iPS-ECs in the presence of QKI-5 maintained a stable phe-
notype for many passages without drifting to various non-
endothelial phenotypes (as it has already been shown in Fig.
2), we further investigated whether QKI-5 had a similar role
in mature ECs. For these experiments, QKI-5 was overex-
pressed in HUVECs by lentiviral gene transfer. These lentiviral
constructs expressed mCherry, and the efﬁciency of infection
was monitored by in vivo imaging using a ﬂuorescence micro-
scope (Fig. 7A). Indeed, QKI-5 was highly overexpressed in
these mature ECs (Fig. 7B) and was able to induce further the
expression of CD144 and VEGFA in both protein and mRNA
levels (Fig. 7C, 7D). Importantly, QKI-5 overexpression did not
induce the expression of non-EC markers such as SMA and
SM22 (Fig. 7C). These results highlight that QKI-5 induces EC
differentiation from hiPSCs and, in parallel, has an important
role in the maintenance of the EC phenotype in both differen-
tiated and mature ECs. Additional experiments with Matrigel
plus assays in vivo provided further support to the above
ﬁndings. hiPSC-ECs OE-QKI-5 signiﬁcantly induced angiogenesis
only 7 days after subcutaneous injection of ECs OE- QKI-5-
iPSCs labeled with Vybrant cell surface marker in SCID mice,
in comparison with the iPS-ECs CTL expressing an empty lenti-
viral vector (HE staining in Fig. 7E). CD31 immunoﬂuorescence
staining conﬁrmed the presence of differentiated cells in in
vivo vascular tubes and demonstrated that QKI-5 over-
expressing iPSCs displayed well-formed vascular structures
(Fig. 7G) and enhanced engraftment ability when co-stained
with CD144 and Vybrant compared with the control cells (Fig.
7F, 7H). In addition, a human speciﬁc antibody for CD31 was
used to stain exclusively the human cells in the Matrigel plugs
and co-stained with the Vybrant to conﬁrm the presence of
the human cells and the speciﬁcity of the Vybrant labeling
(Fig. 7I). These results clearly demonstrate that QKI-5 induced
angiogenesis in vivo Matrigel plug assays highlighting its pivot-
al role in EC differentiation derived from hiPSCs.
DISCUSSION
iPSCs represent an attractive cellular approach for regenera-
tive medicine today as they can be used to generate thera-
peutic cells of almost any type and, importantly, can be
harnessed as patient-speciﬁc cells toward autologous cell ther-
apy. In this study, using the model of iPSCs differentiation
toward ECs, the RNA-binding protein QKI-5 was found to be
an important regulator of VE-cadherin stabilization and
VEGFR2 transcriptional activation during the EC differentiation
process. Notably, QKI-5 overexpression induced the activation
of EC markers, while knockdown by shRNA suppressed EC dif-
ferentiation. In this study, the role of QKI-5 has been elucidat-
ed in EC differentiation from iPSCs. iPSCs have been
generated based on a highly efﬁcient approach, fully charac-
terized and forced to differentiate toward ECs. QKI-5 was
found to be induced during EC differentiation from iPSCs, and
its expression was shown to be maintained at high levels in
mature ECs. It has been demonstrated that QKI-5 plays a role
in the induction and stabilization of CD144 and activation of
VEGFR-regulatory binding sites AP1 and STAT3 and induction
of STAT3 phosphorylation. Importantly, QKI-5 modulated the
activation of VEGFR through direct binding of the 30 UTR
region of STAT3. The notion that QKI-5 indeed played an
important role during EC differentiation was further supported
from additional data which clearly demonstrated that knock-
down of QKI-5 resulted in inhibition of angiogenesis in vivo.
Remarkably, ECs derived from iPS OE-QKI-5 improved neovas-
cularization and blood ﬂow recovery (almost 100%) in a hind
limb ischemia model by showing an enhanced engraftment
capacity when compared with non-modiﬁed iPS-ECs or PBS
control groups. Notably, hiPSCs OE-QKI-5 induced angiogenesis
in Matrigel plug assays in vivo only 7 days after subcutane-
ously injection in SCID mice, highlighting a clear functional
beneﬁt of QKI-5 in neovascularization, blood ﬂow recovery,
and angiogenesis.
RNA-binding proteins add an additional layer of complexi-
ty to a series of events, which include processing and splicing
of pre-mRNA, export to the cytoplasm, quality control
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Figure 6. QKI-5 has a key role in endothelial cell (EC) differentiation derived from human induced pluripotent stem cells (hiPSCs). (A):
hiPSCs were generated and differentiated on low attachment plates using StemPro serum free media supplemented with BMP4, Activin
A, ﬁbroblast growth factor, and vascular endothelial growth factor (VEGF) for 5 days. KDR (VEGFR) positive population was selected
using MicroBeads and cultured on Fibronectin coated plates supplemented with EGM-2 media for 3–9 days. iPS-ECs-derived cells
expressed a typical pattern for EC speciﬁc markers CD144, CD31, eNOS, and vWF as immunoﬂuorescence images shown. (B): FACs analy-
sis showing cells positive for EC speciﬁc marker CD144 (C, D) QKI-5 was expressed during EC differentiation in parallel with VE-cadherin
expression in mRNA level. (E–G) QKI-5 was overexpressed by lentiviral gene transfer in hiPSCs on day 3 after KDR selection and the cells
were harvesting on day 6 of EC differentiation showing a signiﬁcant induction of the EC markers CD144, CD31, and eNOS, and signaling
of VEGFR (KDR), VEGFA, and STAT3 as Western blots and real time data shown. (H, I) Luciferase assays shown that QKI-5 induced the
transcriptional activation of CD144 and VEGFR. (J): Overexpression of QKI-5 directs differentiation toward arterial EC as cells express speciﬁc
marker Ephrin B2 and not venous (CoupTFII) or lymphatic (Lyve1) ECmarkers (data are means6 SEM [n5 3]; *, p< .05; **, p< .01). Abbrevia-
tions: CTL, control; EC, endothelial cell; hiPSC, human induced pluripotent stem cell; iPSC, induced pluripotent stem cell.
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assessment of mRNA through translation, message decay and stabilization, and translational repression and de-repression
Figure 7. QKI-5 induced CD144 and VEGFA expression in human umbilical vein endothelial cells (HUVECs) and Human iPS-endothelial
cells (ECs) overexpressing QKI-5 induced angiogenesis in vivo. (A): QKI-5 was overexpressed in HUVECs by lentiviral gene transfer. The
efﬁciency of infection was monitored by the mCherry expression. (B, C): QKI-5 was highly overexpressed in mature ECs and induced fur-
ther the expression of CD144 and VEGFA (C, D), but it did not induce non-EC markers such as SMA and SM22 in the mRNA level (D)
(data are means6 SEM. (n5 3); *, p< .05; **, p< .01). Scale bar5 50 mm. Human iPS-ECs were forced to overexpress QKI-5 by lentivi-
ral gene transfer on day 3 of EC differentiation after KDR selection. On day 6, iPS-ECs overexpressing an empty lentiviral vector or iPS-
QKI-5-ECs were labeled with Vybrant Cell Labeling and subcutaneously injected in SCID mice. (E): iPS-QKI-5-ECs signiﬁcantly formed well-
deﬁned vascular structures at 7 days in comparison with the control where less or none formed vascular structures were observed as
H&E staining shown. (F): Frozen section of CD31 immunoﬂuorescence staining conﬁrmed the presence of differentiated cells in in vivo
vascular tubes. (G, H): Enhanced engraftment ability of iPS-QKI-5-ECs was observed when co-stained with CD144 and Vybrant compared
to the control iPS-ECs. Scale bar5 50 mm. (I): Further staining using human speciﬁc CD31 antibody conﬁrms the presence of human cells
and speciﬁcity of the Vybrant in samples seen in (G, H). Abbreviations: CTL, control; DAPI, 40,6-Diamidine-20-phenylindole dihydrochlor-
ide; EC, endothelial cell; hiPSC, human induced pluripotent stem cell; HUVEC, human umbilical vein endothelial cell.
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[44]. All of these events, from initiation of transcription by
key transcription factors, to the stability and effective transla-
tion of the message, are regulated by the presence of speciﬁc
nucleotide sequences which are bound by speciﬁc RNA-
binding proteins [45].
CD144 is a strictly endothelial speciﬁc adhesion molecule
and is of vital importance in maintaining and controlling the
endothelial phenotype through appropriate cell–cell contacts
[16]. CD144 is essential during embryonic angiogenesis and,
thus, the elucidation of the underlying mechanisms that regu-
late CD144 are important in understanding the functions per-
meating vascular permeability, cell proliferation, apoptosis,
and modulation of VEGFR. A recent study has shown that QKI
directly binds to the 30 UTR of CD144 [46]. In our study, we
provide further support to the above notion that QKI-5
induced the mRNA stabilization of CD144.
VEGFA is one of the earliest markers for the endothelial
lineage during development [47, 48], and this growth factor is
also critical for vascular repair and neovascularization [49].
The data obtained in this study indicate that QKI-5 regulates
EC expression of VEGFA and autocrine stimulation of VEGFR
and this pathway is controlled, at least in part, through STAT3
activation and phosphorylation. Interestingly, knockdown of
STAT3 by shRNA ablated QKI-5-mediated activation of the
VEGFR and subsequent expression of EC markers. It has been
reported that constitutive STAT3 activity up-regulates VEGFR
[50], while STAT3 protein binds to the VEGFR promoter induc-
ing VEGFR promoter activity [50]. Interestingly, QKI-5 regu-
lates the expression of STAT3 through direct binding in the
30UTR leading to mRNA stabilization. Notably, the KH
DOMAIN-mutant QKI-5 construct did not induce the expres-
sion of the EC markers, STAT3 signaling when it was overex-
pressed in iPSCs. Importantly, QKI-5 was unable to activate
the 30UTR of STAT3 when the QKI motif was deleted. These
results demonstrate that QKI-5 binds to the 30UTR of STAT3 in
the JAK1-STAT3 signaling pathway and regulates EC differentia-
tion toward an arterial lineage.
It has previously been reported that QKI-5 knockout mice
display a range of blood vessel defects during development
which result in embryonic lethality [39]. Additional studies of
the extraembryonic yolk sac have also reported that QKI regu-
lates visceral endoderm differentiated function at the cellular
level, including the local synthesis of retinoic acid [29], which
then exerts paracrine control of ECs within the adjacent
mesoderm. QKI is also highly expressed during normal cardiac
development, particularly in the outﬂow tract, suggesting
potentially unique functions in the developing heart [51] and
vascular smooth muscle cell development [38]. Taken togeth-
er, this is strong evidence that QKI is highly conserved in the
early embryo throughout the evolution of nonvertebrate and
vertebrate organisms [29]. The role of QKI in the adult organ-
ism is less well-appreciated, although there is evidence that it
could have a role in vascular smooth muscle cell phenotypic
plasticity and can ameliorate pathogenic, ﬁbroproliferative
responses to vascular injury [52].
This study provides strong evidence that QKI-5 is capable
of inducing differentiation toward ECs and that, in parallel,
regulates angiogenesis in both in vitro and in vitro Matrigel
plus assays, even in the absence of exogenous VEGF. At the
moment, the potential of iPSCs to differentiate toward thera-
peutic cells is only based on directed empiricism, while they
are totally dependent on combinations of growth factors,
media, and matrices to favor the desired lineage. In regards
to vascular regeneration, it is important to understand the
key regulatory pathways such as epigenetic alterations, tran-
scriptional activity, and RNA-binding patterns associated with
the differentiation processes. In particular, although there has
been signiﬁcant progression in the ﬁeld [53], there are not
any fully deﬁned protocols to generate high-ﬁdelity and stable
ECs from human pluripotent stem cells at the moment. This is
a major limitation of generating pure populations of rejuve-
nated EC cells to be used for drug screening and cell-based
therapies. Indeed, QKI-5 is a very interesting candidate, which
holds the potential to derive stable populations of functional
ECs. Speciﬁcally, the transcription factor ETS1 is implicated in
the induction of the expression of QKI-5 during early stages of
EC differentiation. QKI-5 is also acting as a splicing factor
involved in the regulation of numerous signaling pathways.
Data from our laboratory also showed that QKI-5 induced the
splicing factor SF3B1 during EC differentiation (Supporting
Information Fig. S9). Importantly, SF3B1 is induced in a time-
dependent manner during EC differentiation from iPSCs (Sup-
porting Information Fig. S10), indicating that QKI-5 is likely to
be an important splicing regulator of EC differentiation. Nota-
bly, a number of QKI splicing isoforms have been reported,
although their function(s) are not clearly deﬁned. Additional
studies are clearly required to shed light on the precise func-
tions of the different QKI splicing isoforms. Interestingly, a
recent paper has reported that QKI plays a remarkably dynam-
ic role in regulating hundreds of circular RNAs (circRNAs) dur-
ing human epithelial to mesenchymal transition (EMT), while
QKI itself is regulated during EMT [16]. Therefore, it is tempt-
ing to speculate that precise regulation of QKI-5 during EC dif-
ferentiation will provide fully deﬁned experimental protocols,
which could reproducibly guide iPSCs to a vascular lineage [54,
55] and, thereby, enable clinical application [56–58]. In addi-
tion, it would be very interesting to investigate the role of QKI
and its mRNA splicing isoforms in disease models, such as ath-
erosclerosis and diabetes, where the endothelial function is
impaired.
SUMMARY
In summary, our data strongly support the notion that QKI-
5 is induced during EC differentiation, resulting in stabiliza-
tion of STAT3 expression through direct binding to the 30
UTR region of STAT3, modulation of VEGFR transcriptional
activation and VEGF secretion. Markedly, iPS-ECs OE-QKI-5
signiﬁcantly improved angiogenesis and neovascularization
and blood ﬂow recovery in experimental hind limb ische-
mia (Supporting Information Fig. S9) highlighting a clear
functional beneﬁt. This study provides support to the grow-
ing consensus that elucidating the molecular mechanisms
underlying EC differentiation will ultimately advance stem
cell regenerative therapy toward treating cardiovascular
disease.
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